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CASE REPORT

Use of Parenteral Fish Oil to Reverse
Cholestasis Induced by Parenteral
Nutrition in Infants with Intestinal Failure:
Single-Centre Case Series
Denise Reniers, Irina Rajakumar, Suzanne Ratko, and Paul Atkison

INTRODUCTION

This case series describes the first 8 consecutive infants at
the authors’ institution for whom therapy with parenteral fish
oil was started (August 2006 to September 2008) after
development of hepatic cholestasis associated with parenteral
nutrition. Six of the patients had necrotizing enterocolitis and
short-bowel syndrome, one patient had very long segment
Hirschsprung disease with short-bowel syndrome, and one
patient had congenital sodium secretory diarrhea and was
dependent on parenteral nutrition. Demographic characteristics and direct bilirubin values at the start of parenteral fish oil
therapy are detailed in Table 1.
For most patients, parenteral fish oil was started when
direct bilirubin was greater than 35 µmol/L. In one case, the

parenteral fish oil was started in the neonatal intensive care
unit at another institution at a slightly lower bilirubin level
(33 µmol/L). In all cases, the parents gave verbal consent before
parenteral fish oil emulsion was started. The emulsion was
initiated at 0.5 g/kg and was increased to 1 g/kg after 2 days.5
The emulsion was prepared in 60-mL syringes to allow delivery
via a syringe pump, with an expiry time of 24 h at room
temperature. The infusion was interrupted as required for
administration of other medications. The parenteral fish oil was
administered for a period ranging from 4.6 to 8.4 months. All
patients had previously received up to 3 g/kg per day of IV
Intralipid, which was discontinued when the parenteral fish oil
was started. Six of the 8 infants were receiving part of their
caloric intake in the form of enteral feeding, which may in part
stimulate bile flow and help to reduce bilirubin.
After the introduction of IV parenteral fish oil therapy,
liver enzyme values (specifically aspartate aminotransferase)
were normalized at a median of 68 days (interquartile range
[IQR] 57–111 days). Total bilirubin normalized (range
3.4-17.1 µmol/L) at a median of 99 days (IQR 75–113 days)
and direct bilirubin at 130 days (IQR 115–135 days).
However, direct bilirubin values were approaching normal
(< 5.1 µmol/L) by day 90 of therapy in most infants (Figure 1).
For one of the patients (patient F), normalization took longer,
presumably because of an underlying liver disease that was
still undiagnosed at the time of writing. Liver biopsy suggested
biliary atresia, which has since been ruled out.
The parenteral fish oil therapy was well tolerated and was
not associated with any infusion-related adverse events or
delayed growth. There were no clinical symptoms of essential
fatty acid deficiency, such as dermatitis. However, biochemical
testing for such deficiency was not performed because of a lack
of availability of such testing in Canada. Patient F had some
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ublished data assessing the efficacy and toxicity of omega-3
fatty acid emulsion in children are limited.1-3 Until recently,
children requiring long-term parenteral nutrition who experienced parenteral nutrition–associated liver disease (PNALD)
were likely to die from infection or liver disease before receiving a small bowel and/or liver transplant.4 With the introduction of parenteral fish oil (10% long-chain omega-3 fatty acid
emulsion; Omegaven, Fresenius Kabi, Bad Homburg,
Germany), originally indicated for use in combination with a
soybean oil–based lipid emulsion (Intralipid), we have been
able to reverse this life-threatening condition in several infants
without the need for transplantation. We present our experience with parenteral administration of fish oil in 8 infants with
PNALD. Verbal informed consent for publication was
obtained from the patients’ guardians. No ethics approval was
required by our institution.

CASE SERIES
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Table 1. Baseline Characteristics of 8 Infants who Received Parenteral Fish Oil (PFO)
Data at Start of PFO
Direct Bilirubin
NEC
SBS
Age (wk)
(µmol/L)
Y
Y
32.86
94.3
A
B
Y
Y
12.71
68.4
C
Y
Y
16.43
66.5
D
Y
Y
4.71
35.9
E
N*
N
14.14
51.0
F
Y
Y
3.43
33.1
G
Y
Y
1.86
81.0
H
N†
Y
7.57
46.4
Mean ± SD or
NA
NA
11.71 ± 10.06
58.75
median (IQR)
(43.78–71.55)¶
*IQR = interquartile range, NA = not applicable, NEC = necrotizing enterocolitis, SBS = short-bowel syndrome,
SD = standard deviation.
*Patient had congenital sodium secretory diarrhea.
†Patient had Hirschsprung disease.
Patient

Demographic Characteristics
Gestational
Birth
Age (wk)
Weight (kg)
Sex
31.00
1.695
F
29.86
1.285
F
25.57
0.765
F
26.00
0.865
M
34.43
2.170
F
29.43
0.870
M
36.57
2.517
M
40.00
3.775
M
31.61 ± 5.06
1.743 ± 1.043
NA

Clinical Scenario

Figure 1. Bilirubin values for individual patients in the case series.
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rectal bleeding associated with elevation of the international
normalized ratio (INR), but there was no change in
hemoglobin, and transfusion was not required.

DISCUSSION
PNALD occurs in 40% to 60% of infants who require
parenteral nutrition for 1 to 3 months, with the incidence
increasing to 85% among those who receive parenteral
nutrition for more than 100 days.1,6 Some evidence suggests
that infants with short-bowel syndrome and direct bilirubin
levels remaining above 3 mg/dL (51.3 µmol/L) for more than
3 months are at increased risk of death from liver failure.5
Furthermore, direct bilirubin above 4 mg/dL (68.4 µmol/L) for
longer than 6 months was correlated with a mortality rate
of 78%.7 Most patients in the current case series had direct
bilirubin values approaching normal by day 90 of therapy with
parenteral fish oil (Figure 1).
Although parenteral fish oil is generally available in
Europe, it is available in Canada and the United States only
with approval from the pertinent federal regulatory body. This
type of therapy should not be administered to patients with
allergy to fish or egg protein and should be used with caution
in patients requiring anticoagulant therapy, as the parenteral
fish oil may prolong bleeding time and inhibit platelet aggregation.8 Of note in the current case series, patient F had
abnormal values for INR and partial thromboplastin time
(PTT) during therapy with parenteral fish oil because of bleeding problems during a period when results for bilirubin and
liver function tests had normalized. The INR normalized with
parenteral administration of vitamin K. At the study institution, INR and PTT values are not routinely measured for
patients with otherwise normal liver enzymes and function who
are receiving parenteral nutrition; as such, we do not have
values for other patients to which comparisons could be made.
All of the infants in this case series experienced bacterial
infections with enteric organisms, which is a common complication of long-term parenteral nutrition through a central

venous catheter.7 One of the patients (patient A) experienced
neutropenic episodes while in hospital (neutrophil count 0.5 ×
109/L to 1.0 × 109/L), but these episodes did not directly
correlate with the onset of bacterial infection or initiation of
parenteral fish oil therapy and persisted after the therapy was
discontinued. Three of the patients (patients A, B, and G)
required oral selenium supplementation. Parenteral nutrition
with trace elements was started for all patients; however, copper
and manganese were excluded to limit potential worsening of
PNALD and accumulation of these trace minerals.1,7 Children
receiving long-term parenteral nutrition should undergo serum
micronutrient monitoring to ensure adequate intake and to
prevent accumulation.
The cause of PNALD is not well understood. Proposed
mechanisms include the use of soybean and safflower oil–based
fat emulsions rich in omega-6 fatty acids, which have
pro-inflammatory properties potentially leading to liver injury.
Phytosterols found in soybean lipid emulsions are postulated to
reduce bile flow, leading to formation of biliary sludge. In one
study, children with severe parenteral nutrition–associated
cholestasis had high phytosterol levels,7 but no direct
correlation has been demonstrated between phytosterols and
development of cholestasis in patients receiving lipid
emulsions.4 Parenteral fish oil contains mostly omega-3 fatty
acids, which have anti-inflammatory properties and lack
phytosterols, and it is the presence of this type of fatty acid that
may play a role in improving bile flow and improving hepatic
cholestasis. In a previous study, the use of parenteral fish oil in
a small subset of patients resulted in a shorter time to reversal
of cholestasis relative to patients who received soybean oil
emulsion, with no difference in essential fatty acid levels or
infection rates.3
In the study reported here, the use of parenteral fish oil
reversed parenteral nutrition–induced cholestasis in all 8
patients over a median period of 18.6 weeks. The median time
to normalization in previously published reports has ranged
from 8 weeks to 8 months.2,3,5 In 2 patients, serum bilirubin
levels normalized without enteral nutrition (patients E and H;

Table 2. Nutrition When Bilirubin Values Normalized
Total Calories Delivered
Protein Delivered
Patient
Dose (kcal/kg) % from Enteral Dose (g/kg) % from Enteral
A
100
100
3.1
100
B
100
83
2.9
90
C
112
72
3.2
68
D
111
49
3.1
26
E
94
0
3.0
0
F
98
56
3.2
53
G
109
31
3.6
17
H
80
0
3.2
0
PFO = parenteral fish oil.
*Patient was receiving soybean emulsion 1 day/week at a dose of 3.5 g/kg.
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PFO (g/kg)
0
0
0.98
1
1*
0.99
0.96
0.98
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see Table 2), which correlates with previously reported results.3
Reversal of cholestasis may also be achieved by limiting or
temporarily withholding soybean oil emulsion.9,10
Eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are derivatives of linolenic acid. Linolenic acid (along
with linoleic acid) is an essential fatty acid necessary for brain
development. EPA and DHA make up greater than 50% of
the fatty acid content of parenteral fish oil.11 There has been
concern that utilization of parenteral fish oil may lead to
essential fatty acid deficiency. In a previously published case
series, one patient exhibited biochemical evidence of essential
fatty acid deficiency at 4 weeks, despite a lack of clinical
evidence.3 The patient was not receiving parenteral fish oil
therapy at the time of these abnormal results. Parenteral fish oil
was reintroduced, and the biochemical markers returned to
normal. Other reports of patients with essential fatty acid
deficiency while receiving parenteral fish oil alone (1 g/kg) have
been published.12-14 In view of this potential problem, patient E
was given Intralipid (3.5 g/kg) 1 day/week, as she was unable to
tolerate even small amounts of enteral feeds and was therefore
fed solely by parenteral nutrition. At the time of writing, the
long-term outcomes for children maintained on parenteral fish
oil as their sole source of fat is generally unknown.
To date, only a few case reports of success with parenteral
fish oil for hepatic cholestasis have been published.2,3,5 Further
studies are needed to determine if initiation of treatment with
this form of therapy, alone or in combination with soybean
oil emulsion, in cases with anticipated long-term need for
parenteral nutrition, will prevent hepatic cholestasis. In
addition, larger studies in the pediatric population are needed
to further evaluate the safety and efficacy of parenteral fish oil
for the prevention and reversal of hepatic dysfunction
secondary to parenteral nutrition.3 A prospective, randomized
trial is currently under way to evaluate and compare the
efficacy of fish oil–based emulsion and conventional soybean
oil emulsion in the prevention of cholestasis.15 These data will
facilitate decision-making regarding the appropriate time to
initiate therapy with parenteral fish oil.
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